Shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) have earned a consensus rating of “Buy” from the six analysts that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $3.80.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Ocera Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a report on Saturday, August 26th. Aegis restated a “buy” rating and issued a $3.00 price objective on shares of Ocera Therapeutics in a report on Wednesday, May 24th. Finally, HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Ocera Therapeutics in a report on Wednesday, May 10th.

ILLEGAL ACTIVITY WARNING: “Analysts Set Ocera Therapeutics, Inc. (OCRX) Price Target at $3.80” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/04/analysts-set-ocera-therapeutics-inc-ocrx-price-target-at-3-80.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu KCG Holdings LLC raised its stake in Ocera Therapeutics by 194.6% during the 2nd quarter. Virtu KCG Holdings LLC now owns 213,531 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 141,040 shares during the last quarter. Hikari Power Ltd raised its stake in Ocera Therapeutics by 50.6% during the 2nd quarter. Hikari Power Ltd now owns 376,596 shares of the biopharmaceutical company’s stock valued at $437,000 after buying an additional 126,596 shares during the last quarter. Renaissance Technologies LLC raised its stake in Ocera Therapeutics by 17.9% during the 4th quarter. Renaissance Technologies LLC now owns 219,100 shares of the biopharmaceutical company’s stock valued at $460,000 after buying an additional 33,300 shares during the last quarter. Finally, Perceptive Advisors LLC purchased a new stake in Ocera Therapeutics during the 1st quarter valued at $2,817,000. Institutional investors own 20.25% of the company’s stock.

Shares of Ocera Therapeutics (NASDAQ:OCRX) traded up 5.0000% during mid-day trading on Wednesday, hitting $0.9765. The company had a trading volume of 180,888 shares. The firm has a 50-day moving average price of $1.07 and a 200-day moving average price of $1.11. The firm’s market capitalization is $25.89 million. Ocera Therapeutics has a 52 week low of $0.52 and a 52 week high of $3.15.

Ocera Therapeutics (NASDAQ:OCRX) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. Ocera Therapeutics had a negative net margin of 4,416.26% and a negative return on equity of 175.02%. Equities analysts forecast that Ocera Therapeutics will post ($1.20) earnings per share for the current year.

Ocera Therapeutics Company Profile

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Analyst Recommendations for Ocera Therapeutics (NASDAQ:OCRX)

Receive News & Stock Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related stocks with our FREE daily email newsletter.